… COVID-19 patients has been associated with survival benefit; however, the optimal
thromboprophylaxis … societies regarding thromboprophylaxis strategies in COVID-19 patients in …

… with COVID-19, we suggest current standard dose anticoagulant thromboprophylaxis over
… COVID-19, we recommend inpatient thromboprophylaxis only over inpatient plus extended …

… coronavirus disease 2019 (COVID-19). We would like to offer further information about
thromboprophylaxis … been admitted to hospital with COVID-19. Tang and colleagues1 described a …

… We reviewed anti-FXa activity in patients admitted to hospital with COVID-19 infection, all
receiving pharmacological thromboprophylaxis with enoxaparin 40 mg once daily, creatinine …

Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. …

… for thromboprophylaxis are necessary in COVID‐19 patients hospitalized in general wards
… mg bid versus 40 mg od enoxaparin in COVID‐19 patients, between April 30 2020 and April …

… of coagulopathy in COVID-19 recommends prophylactic … Following initial case reports on
PE in COVID-19 patients,[14] a … In this study, pharmacological thromboprophylaxis was not …

… VTE risk stratification among COVID-19 patients. This study … levels among anticoagulated
COVID-19 patients with and … among COVID-19 patients who received thromboprophylaxis on …

… pharmacologic thromboprophylaxis in hospitalized patients with COVID-19 coupled with …
We compared summary thrombosis rates in hospitalized patients with COVID-19 stratified by …

… Additional important questions pertaining to thromboprophylaxis in COVID-19 …
thromboprophylaxis and the effect of outpatient thromboprophylaxis for patients with mild COVID-19 …